Dose equivalence of two commercial preparations of botulinum neurotoxin type A: Time for a reassessment?

Current Medical Research and Opinion

Volumn 25, Issue 7, 2009, Pages 1573-1584

  Wohlfarth, Kai ^a   Sycha, Thomas ^b   Ranoux, Danièle ^c   Naver, Hans ^d   Caird, David ^e  

^a BG KLINIKEN BERGMANNSTROST   (Germany)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

^c LIMOGES UNIVERSITY HOSPITAL   (France)

^d Nykoping Hospital   (Sweden)

^e IDS SCHEER AG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BOTULINUM TOXIN A; BUFFER; DILUENT; GELATIN; PHOSPHATE; SODIUM CHLORIDE;

ANIMAL EXPERIMENT; CONTROLLED STUDY; DIFFUSION; DRUG ACTIVITY; DRUG POTENCY; DRUG SYNTHESIS; ELECTROMYOGRAM; EXTENSOR MUSCLE; FACE; MOUSE; NONHUMAN; NOTE; PH;

ANIMALS; BOTULINUM TOXINS, TYPE A; COMMERCE; DOSAGE FORMS; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMAN EXPERIMENTATION; HUMANS; PHARMACEUTICAL PREPARATIONS; THERAPEUTIC EQUIVALENCY;

EID: 67650433813     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007990903028203     Document Type: Note

References (50)

1. Grumelli C, Verderio C, Pozzi D, et al. Internalization and mechanism of action of clostridial toxins in neurons. Neurotoxicology 2005;26:761-7
2. Truong D, Duane DD, Jankovic J, et al. Efficacy and safety of botulinum type A toxin (Dysport) in cervical dystonia: results of the first US randomized, double-blind, placebo-controlled study. Mov Disord 2005;20:783-91
3. Tsai CP, Chiu MC, Yen DJ, et al. Quantitative assessment of efficacy of dysport (botulinum toxin type A) in the treatment of idiopathic blepharospasm and hemifacial spasm. Acta Neurol Taiwan 2005;14:61-8
4. Hsiung GY, Das SK, Ranawaya R, et al. Long-term efficacy of botulinum toxin A in treatment of various movement disorders over a 10-year period. Mov Disord 2002;17: 1288-93
5. Bakheit AM, Pittock S, Moore AP, et al. A randomized, doubleblind, placebo-controlled study of the efficacy and safety of botulinum toxin type A in upper limb spasticity in patients with stroke. Eur J Neurol 2001;8:559-65
6. Felber ES. Botulinum toxin in primary care medicine. J Am Osteopath Assoc 2006;106:609-14
7. Suputtitada A, Suwanwela NC. The lowest effective dose of botulinum A toxin in adult patients with upper limb spasticity. Disabil Rehabil 2005;27:176-84
8. Leippold T, Reitz A, Schurch B. Botulinum toxin as a new therapy option for voiding disorders: current state of the art. Eur Urol 2003;44:165-74
9. Gui D, Rossi S, Runfola M, et al. Review article: botulinum toxin in the therapy of gastrointestinal motility disorders. Aliment Pharmacol Ther 2003;18:1-16
10. Carruthers A, Carruthers J. Botulinum toxin type A: history and current cosmetic use in the upper face. Semin Cutan Med Surg 2001;20:71-84
11. McLellan K, Das RE, Ekong TA, et al. Therapeutic botulinum type A toxin: factors affecting potency. Toxicon 1996;34: 975-85
12. Marchetti A, Magar R, Findley L, et al. Retrospective evaluation of the dose of Dysport and BOTOX in the management of cervical dystonia and blepharospasm: the REAL DOSE study. Mov Disord 2005;20:937-44
13. Brin MF, Blitzer A. Botulinum toxin: dangerous terminology errors. J R Soc Med 1993;86:493-4
14. Sampaio C, Costa J, Ferreira JJ. Clinical comparability of marketed formulations of botulinum toxin. Mov Disord 2004;19(Suppl 8):S129-36
15. Hambleton P, Pickett AM. Potency equivalence of botulinum toxin preparations. J R Soc Med 1994;87:719
16. Pickett AM, Hambleton P. Dose standardisation of botulinum toxin. Lancet 1994;344:474-5
17. Pearce LB, Borodic GE, First ER, et al. Measurement of botulinum toxin activity: evaluation of the lethality assay. Toxicol Appl Pharmacol 1994;128:69-77
18. Van den Bergh PY, Lison DF. Dose standardization of botulinum toxin. Adv Neurol 1998;78:231-5
19. Sesardic D, Leung T, Gaines Das R. Role for standards in assays of botulinum toxins: international collaborative study of three preparations of botulinum type A toxin. Biologicals 2003;31: 265-76
20. Wohlfarth K, Goschel H, Frevert J, et al. Botulinum A toxins: units versus units. Naunyn Schmiedebergs Arch Pharmacol 1997;355:335-40
21. Bigalke H. Botulinumtoxine: Wirksamkeit und Antigenizitaet. Klin Neurophysiol 2001;32:210-12
22. Aoki KR. A comparison of the safety margins of botulinum neurotoxin serotypes A, B, and F in mice. Toxicon 2001;39:1815-20
23. Aoki K. Preclinical update on Botox (botulinum toxin type A)-purified neurotoxin complex relative to other botulinum neurotoxin preparations. Eur J Neurol 1999;6(Suppl 4):3-10
24. Rosales RL, Bigalke H, Dressler D. Pharmacology of botulinum toxin: differences between type A preparations. Eur J Neurol 2006; 13(Suppl 1):2-10
25. Poulain B, Popoff MR, Molgó J. How do the Botulinum Neurotoxins block neurotransmitter release: from botulism to the molecular mechanism of action. Botulinum J 2008; 1:14-87
26. Friday D, Bigalke H, Frevert J. In vitro stability of botulinum toxin complex preparations at physiological pH and temperature. Naunyn Schmiedebergs Arch Pharmacol 2002; 365(Suppl 2)
27. Simpson LL. Identification of the major steps in botulinum toxin action. Annu Rev Pharmacol Toxicol 2004;44:167-93
28. Schantz EJ, Johnson EA. Properties and use of botulinum toxin and other microbial neurotoxins in medicine. Microbiol Rev 1992;56:80-99
29. Eisele K-H, Taylor HV. Dissociation of the 900 kDa neurotoxin complex for C. botulinum under physiological conditions. Toxicon 2008;51:28
30. Wohlfarth K, Schwandt I, Wegner F, et al. Biological activity of two botulinum toxin type A complexes (Dysport® and Botox®) in volunteers: a double-blind, randomized, dose-ranging study. J Neurol 2008;255:1932-9
31. Wohlfarth K, Muller C, Sassin I, et al. Neurophysiological double-blind trial of a botulinum neurotoxin type a free of complexing proteins. Clin Neuropharmacol 2007;30:86-94
32. Sloop RR, Escutin RO, Matus JA, et al. Dose-response curve of human extensor digitorum brevis muscle function to intramuscularly injected botulinum toxin type A. Neurology 1996;46:1382-6
33. Kreyden OP, Scheidegger EP. Anatomy of the sweat glands, pharmacology of botulinum toxin, and distinctive syndromes associated with hyperhidrosis. Clin Dermatol 2004;22:40-4
34. Kranz G, Haubenberger D, Voller B, et al. Respective potencies of Botox(R) and Dysport(R) in a human skin model: a randomized, double-blind study. Mov Disord 2009;24:231-6
35. Hexsel D, Dal'Forno T, Hexsel C, et al. A randomized pilot study comparing the action halos of two commercial preparations of botulinum toxin type A. Dermatol Surg 2008; 34:52-9
36. Rystedt A, Swartling C, Naver H. Anhidrotic effect of intradermal injections of botulinum toxin: a comparison of different products and concentrations. Acta Derm Venereol 2008; 88:229-33
37. Karsai S, Adrian R, Hammes S, et al. A randomized doubleblind study of the effect of Botox and Dysport/Reloxin on forehead wrinkles and electromyographic activity. Arch Dermatol 2007;143:1447-9
38. Trindade de Almeida AR, Marques E, de Almeida J, et al. Pilot study comparing the diffusion of two formulations of botulinum toxin type A in patients with forehead hyperhidrosis. Dermatol Surg 2007;33(1 Spec No.):S37-43
39. Rystedt A, Swartling C, Farnstrand C, et al. Equipotent concentrations of Botox and Dysport in the treatment of palmar hyperhidrosis. Acta Derm Venereol 2008;88:458-61
40. Clarke M, Oxman AD, eds. Cochrane Reviewers' Handbook 4.1.5 [updated April 2002]. Oxford: Update Software. Updated quarterly, 2002.
41. Odergren T, Hjaltason H, Kaakkola S, et al. A double blind, randomised, parallel group study to investigate the dose equivalence of Dysport and Botox in the treatment of cervical dystonia. J Neurol Neurosurg Psychiatry 1998;64:6-12
42. Ranoux D, Gury C, Fondarai J, et al. Respective potencies of Botox and Dysport: a double blind, randomised, crossover study in cervical dystonia. J Neurol Neurosurg Psychiatry 2002;72:459-62
43. Nussgens Z, Roggenkamper P. Comparison of two botulinumtoxin preparations in the treatment of essential blepharospasm. Graefes Arch Clin Exp Ophthalmol 1997;235:197-9
44. Sampaio C, Ferreira JJ, Simoes F, et al. DYSBOT: a singleblind, randomized parallel study to determine whether any differences can be detected in the efficacy and tolerability of two formulations of botulinum toxin type A - Dysport and Botox - assuming a ratio of 4:1. Mov Disord 1997;12: 1013-18
45. Poewe W. Respective potencies of Botox and Dysport: a double blind, randomised, crossover study in cervical dystonia. J Neurol Neurosurg Psychiatry 2002;72:430
46. Talarico-Filho S, Mendonca DONM, Sperandeo DEMF, C DESP. A double-blind, randomized, comparative study of two type A botulinum toxins in the treatment of primary axillary hyperhidrosis. Dermatol Surg 2007;33(1 Spec No.):S44-50.
47. Simonetta Moreau M, Cauhepe C, Magues JP, et al. A doubleblind, randomized, comparative study of Dysport vs. Botox in primary palmar hyperhidrosis. Br J Dermatol 2003;149: 1041-5
48. Lowe P, Patnaik R, Lowe N. Comparison of two formulations of botulinum toxin type A for the treatment of glabellar lines: a double-blind, randomized study. J Am Acad Dermatol 2006;55:975-80
49. Rzany B, Nast A. Head-to-head studies of botulinum toxin A in aesthetic medicine: which evidence is good enough? J Am Acad Dermatol 2007;56:1066-7
50. Kollewe K, Buhr N, Krampfl K, et al. Long-term follow-up of cervical dystonia patients treated with Botulinum toxin A. Parkinsonism Relat Disord 2008;13(Suppl 2):Abstract 1.254